{"id":786947,"date":"2023-09-28T18:45:44","date_gmt":"2023-09-28T22:45:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novo-integrated-sciences-signs-master-collateral-transfer-agreement\/"},"modified":"2023-09-28T18:45:44","modified_gmt":"2023-09-28T22:45:44","slug":"novo-integrated-sciences-signs-master-collateral-transfer-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novo-integrated-sciences-signs-master-collateral-transfer-agreement\/","title":{"rendered":"Novo Integrated Sciences Signs Master Collateral Transfer Agreement"},"content":{"rendered":"

<\/p>\n

Novo Integrated Sciences Signs Master Collateral Transfer Agreement<\/b><\/p>\n

One Billion Dollar Collateral Transfer through Blacksheep Trust<\/i><\/p>\n

BELLEVUE, Wash.–(BUSINESS WIRE<\/a>)–
\nNovo Integrated Sciences, Inc. (NASDAQ: NVOS) (the \u201cCompany\u201d or \u201cNovo\u201d), today announced Novo and Blacksheep Trust have signed a One Billion Dollar Master Collateral Transfer Agreement (the \u201cMaster Agreement\u201d) for the purpose and general use of monetization by Novo for a period of up to 15 years. The One Billion Dollar collateral transfer is expected to occur in one or more transactions during the current fiscal quarter following the validation and authentication by third-party audit procedures.<\/p>\n

\nRobert Mattacchione, Novo\u2019s CEO and Chairman of the Board, stated, \u201cNovo has secured its core business capital needs with previously disclosed financings and financing opportunities. We believe the pending monetization of this One Billion Dollar collateral transfer transaction represents the solution to the Company\u2019s hypergrowth expectations, and this transaction will allow the Company to proceed with its international growth objectives. We expect our ability to leverage this collateral will provide us with a self-sufficient capital platform ensuring opportunistic and strategic advantage.\u201d<\/p>\n

About Novo Integrated Sciences, Inc.<\/span><\/b><\/p>\n

\nNovo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.<\/p>\n

\nWe believe that \u201cdecentralizing\u201d healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient\/practitioner relationship to the patient\u2019s home and away from on-site visits to primary medical centers with mass-services. This acceleration of \u201cease-of-access\u201d in the patient\/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.<\/p>\n

\nThe Company\u2019s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:<\/p>\n